NCT Number: NCT00150553
Efficacy and Safety of SPD417 in Treatment of Manic Symptoms in Adults With Bipolar I Disorder
The purpose of this study is to compare the efficacy and safety of SPD417 in treating bipolar manic symptoms, when given once daily in the evening vs. twice daily.
Looking for future studies?
Notify MeKey information
Age range
18 year and older
Sex eligibility
All sexes
Study type
Interventional
Phase
Phase 3
Who can participate
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
- DSM-IV criteria for bipolar I disorder
- Screen YMRS score => 16
- Women of childbearing potential agree to take adequate precautions against contraception
Exclusion criteria
- Hospitalization required for treatment of psychiatric symptoms
- Patients who meet DSM-IV for ultra-rapid cycling
- History of serious suicide attempt requiring medical intervention
Treatment and study plan
Primary outcomes
-
Score on Young Mania Rating Scale (YMRS) at 12 weeks
Secondary outcomes
-
Time to remission
-
Clinical Global Impressions Scale - Bipolar Version
-
HAM-D and MADRS scales for depression
Interested in participating?
Looking for future studies?
Notify MeSponsors and collaborators
Lead sponsor
Validus Pharmaceuticals
Industry
Registry information
Official study title
A Phase IIIb, Randomized, Double-Blind, Parallel Group Study in Bipolar I Patients to Assess the Efficacy and Safety of SPD417 Administered Once Daily vs Twice Daily in the Treatment of Manic Symptoms
Important dates
- Study start
- 2005
- Study completion
- 2005
- First posted
- Sep 8, 2005
- Registry last updated
- Nov 2, 2007
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Related clinical trials
Published trials that share one or more normalized conditions with this study.
Evaluation of the Genetics of Bipolar Disorder
NCT00001174
Anxiety Disorders, Behavior
Bethesda, Maryland, United States
View Trial DetailstRNS in Anterior Cingulate Cortex Reduces Craving Over Dual Pathology Patients
NCT01876524
Attention Deficit Disorder With Hyperactivity, Attention Deficit Disorder with Hyperactivity
Cartagena, Murcia, Spain
View Trial DetailsIntervention for Comorbid Substance Use and Bipolar Disorders
NCT04202393
Bipolar Disorder, Bipolar and Related Disorders
Providence, Rhode Island, United States
View Trial DetailsGabapentin for Restoring GABA/Glutamate Homeostasis in Co-occurring Bipolar and Cannabis Use Disorders
NCT05064319
Bipolar Disorder, Bipolar I Disorder
Charleston, South Carolina, United States
View Trial Details